Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Summary

The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas. An additional primary objective is to describe the frequency and nature of grade III/IV and grade I/II toxicities associated with this regimen. Secondary objectives include describing 1-year disease-free survival and overall survival rates as well as to estimate clinical and pathologic complete response rates associated with this regimen.

Timeline

Start

2008-07

Primary completion

2011-08

Completion

2011-10

Drugs

Indications